Room For HCV-Focused Start-Ups If The Technology Is Truly Novel
This article was originally published in Start Up
Hepatitis C has been the focus of some of biopharma’s most expensive deals the past couple years. In the wake of the licensing, IPO, and M&A frenzy, not many new start-ups have emerged, but there are a still a few niches to fill if entrepreneurs can find funding.
You may also be interested in...
Gilead released Phase III data Feb. 4 strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.